Semaglutide daily subcutaneous dose-finding trial initiated for Type 2 Diabetes against placebo and liraglutide

Type 2 Diabetes (T2D) is a progressive metabolic disorder characterized by chronic hyperglycemia resulting from impaired insulin secretion and insulin resistance. It affects millions globally, leading to severe micro- and macrovascular complications if not effectively managed. Current therapeutic strategies aim to improve glycemic control, often involving lifestyle modifications and pharmacotherapies. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a cornerstone in T2D management due to their ability to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety, often leading to weight loss. While semaglutide is well-established in once-weekly subcutaneous and daily oral forms, exploring a daily subcutaneous regimen could offer distinct pharmacokinetic profiles or dosing flexibility, potentially optimizing patient outcomes or adherence. This trial addresses the need to define the optimal daily subcutaneous dose of semaglutide and benchmark its performance against existing standards.

This was a global, dose-finding clinical trial investigating daily subcutaneous semaglutide in subjects with Type 2 Diabetes. The study aimed to compare various daily doses of semaglutide against both placebo and once-daily liraglutide to assess their respective efficacy and safety profiles. The specific doses, duration, and primary endpoints were designed to establish an optimal daily subcutaneous regimen for semaglutide.